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Background: Formalin-fixed paraffin-embedded (FFPE) tissue samples are routinely archived in the course of
patient care and can be linked to clinical outcomes with long-term follow-up. However, FFPE tissues have degraded
RNA which poses challenges for analyzing gene expression. Next-generation sequencing (NGS) is rapidly becoming
accepted as an effective tool for measuring gene expressions for research and clinical use. However, the feasibility
of NGS has not been firmly established when using FFPE tissue.
Results: We optimized strategies for whole transcriptome sequencing (RNA-seq) using FFPE tissue. Ribosomal RNA
(rRNA) was successfully depleted by competitive hybridization using the Ribo-zero™ Kit (Epicentre Biotechnologies),
and rRNA sequence content was less than one percent for each library. Gene expression measured by FFPE
RNA-seq was compared to two different standards: RNA-seq from fresh frozen (FF) tissue and quantitative PCR
(qPCR). Both FF and FFPE tumors were sequenced on an Illumina Genome Analyzer IIX with an average of 10
million reads. The distribution of FPKMs (fragments per kilobase of exon per million fragments mapped) and
number of detected genes were similar between FFPE and FF. RNA-seq expressions from FF and FFPE samples
from the same renal cell carcinoma (RCC) correlated highly (r = 0.919 for tumor 1 and r = 0.954 for tumor 2). On
hierarchical cluster analysis, samples clustered by patient identity rather than method of preservation. TaqMan qPCR
of 424 RCC-related genes correlated highly with FFPE RNA-seq expressions (r = 0.775 for FFPE tumor 1, r = 0.803
for FFPE tumor 2). Expression fold changes were considered, to assess biologic relevance of gene expressions.
Expression fold changes between FFPE tumors (tumor 1/tumor 2) correlated well when comparing qPCR and
RNA-seq (r = 0.890). Expression fold changes between tumors from different risk groups (our high risk RCC/The
Cancer Genome Atlas, TCGA, low risk RCC) also correlated well when comparing RNA-seq from FF and FFPE tumors
(r = 0.887).
Conclusions: FFPE RNA-seq provides reliable genes expression data, comparable to that obtained from fresh frozen
tissue. It represents a useful tool for discovery and validation of biomarkers.
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RNA expression profiling may lead to the discovery of
molecular markers for disease diagnosis, assessing progno-
sis, and targeting with drugs. Quantitative (qPCR) has
been the “gold standard” for measuring gene expressions
[1,2] due to its high sensitivity and specificity, reproduci-
bility, and large dynamic range [3-5]. However, next-* Correspondence: Kim: kimhl@cshs.org
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unless otherwise stated.generation sequencing is rapidly becoming accepted [6] as
an effective and more versatile tool for measuring gene ex-
pressions for research and clinical use [7-9]. Compared to
qPCR, the major advantages of next generation sequen-
cing (NGS) include the ability to analyze a sample’s whole
transcriptome in an unbiased way, to discover novel tran-
scripts, and to detect gene fusions, which are common in
cancer [10].
The optimal tissue for RNA-seq is fresh frozen (FF)
tissue with high quality RNA. Unfortunately, frozen tu-
mors are not widely available because they are costly tois an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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embedded (FFPE) tissue samples are routinely archived in
the course of patient care and can often be linked to clinical
outcomes with long-term follow-up. Unfortunately, FFPE
tissues yield relatively low quantities of degraded RNA. A
small number of studies have reported using FFPE tissue
for whole transcriptome mRNA expression profiling
[11-14]. Here, we characterize the performance of RNA-seq
on FFPE renal tumors by comparing results to RNA-seq on
FF renal tumors and qPCR, which is considered the “gold
standard” for measuring gene expression.
In this study, transcriptome-wide RNA-seq was success-
fully performed on matching FFPE and FF clear cell renal
cell carcinomas (ccRCCs). The expression profiles gener-
ated from FFPE and FF tumors correlated well. The tumor
RNA was also assessed by qPCR using the OpenArray®
NT Cycler system, which we’ve previously validated for
use with FFPE tumors [15]. RNA quantities measured
by RNA-seq and qPCR also correlated well. Expression
fold changes between our tumors and tumors from The
Cancer Genome Atlas (TCGA) [7] correlated well when
expressions from FFPE and FF were compared, suggesting
that FFPE RNA-seq can provide biologically meaningful
information. We establish the feasibility of using RNA-seq
with FFPE tissue and recommend its use in future large-
scale RNA-seq studies.
Results
Expression levels determined by qPCR
TaqMan qPCR is an established assay for determining
expression levels using either FF or FFPE tumors. The
OpenArray platform uses microfluidics to load nanoliter
scale TaqMan qPCR chambers. We recently validated
the OpenArray platform for use with FFPE tumors [15].
We conducted a literature review to compile a list of
424 candidate genes relevant to RCC formation, progres-
sion, prognosis and response to treatment (referred to as
RCC genes). The expression of all RCC genes was quan-
tified using the OpenArray platform for the two match-
ing pairs of FFPE and FF RCCs. The optimal reference
genes for normalizing qPCR results (ΔCT) were empiric-
ally determined [16]. As expected, the ΔCT for FFPE
and FF showed good correlation (Figure 1). This con-
firms prior reports that qPCR can be used for expression
profiling of FFPE tissue. It also indicates that the RNA
from our FFPE tumors is of sufficient quality to provide
RNA expressions using qPCR, which can serve as a
standard for comparing with RNA-seq.
Library preparation and RNA-seq
Total RNA was used to prepare libraries for RNA-seq.
Ribosomal RNA (rRNA) constitutes more than 80% of the
total tumor RNA. Therefore, to avoid wasting sequencing
reactions generating repetitive reads, rRNA was removedby competitive hybridization using the Ribo-Zero™ kit.
Total RNA was assessed by Agilent Bioanalyzer before and
after Ribo-Zero treatment to show that large peaks corre-
sponding to 18S and 28S rRNA disappeared (Additional
file 1: Figure S1). The RNA from FFPE tumor is highly
fragmented and the 18S and 28S rRNA peaks were not vis-
ible either before or after Ribo-Zero treatment. Sequencing
libraries were prepared using ScriptSeq™ v2 RNA-Seq Li-
brary Preparation Kit and visualized by E-gel® to confirm
fragment sizes of approximately 300 bp (Figure 2).
Average cluster density for the 4 libraries was approxi-
mately 800 K/mm2. The average depth of sequencing
for each library was 10 million reads. The distribution of
FPKMs for all the genes was similar between FFPE and
FF (Additional file 2: Figure S2). The number of genes
detected by RNA-seq was comparable between FF and
FFPE (Additional file 3: Table S1). The distribution of
detected genes was also comparable between FF and
FFPE (Additional file 4: Figure S3). RNA-seq quality
metrics showed that for each library, greater than 70% of
the reads were uniquely mapped to the genome with less
than 1% being rRNA. The strand specificity was higher
than 80%. (Additional file 3: Table S2).
Comparison of FFPE RNA-seq to established RNA profiling
strategies
RNA-seq is an established platform for quantifying gene
expressions using high quality RNA from FF tissue. To
validate expression profiles generated from highly frag-
ment RNA from FFPE tissue, expression profiles were
compared from matching pairs of FF and FFPE renal tu-
mors. The expressions were highly correlated (Figure 3),
indicating that RNA-seq performs well with FFPE tissue.
The gold-standard for quantifying RNA levels from FFPE
is TaqMan qPCR, which is used for both research and rou-
tine patient care [15,17]. Our panel of 424 RCC genes were
quantified by qPCR using both FF and FFPE tumors and
compared with RNA-seq results. The qPCR results are
expressed on a log2 scale; therefore, FPKM values from
RNA-seq were transformed to a log2 scale. There was high
correlation between expressions determined by qPCR and
RNA-seq for both FF and FFPE tumors (Figure 4). Lower
ΔCT values indicate higher expression while higher FPKM
values indicate higher expression. Figures were plotted
using -ΔCT and FPKM. In a similar analysis, rank correla-
tions were considered because the relationship between
ΔCT and FPKM may not be linear (Figure 4E, Additional
file 5: Figure S4). This analysis confirmed a high correlation
between qPCR and RNA-seq for both FF and FFPE tissue.
FFPE RNA-seq results contain biologically meaningful
information
It is well known that tumor RNAs measured by qPCR or
FF RNA-seq reflect diagnostic and prognostic information
Figure 1 Correlation of qPCR for matched FF and FFPE tumors. A and B) The OpenArray® platform was used to perform TaqMan qPCR for
RCC genes using matching FF and FFPE tumors. C) For qPCR, r (Pearson’s correlation coefficient) was calculated using ΔCT, which is the
normalized cycle threshold for each gene. FF, fresh frozen; FFPE, formalin-fixed paraffin-embedded.
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ical profiles. However they are expected to be molecularly
distinct, particularly when the RCC genes are considered.
Therefore, fold changes were calculated for each gene
comparing tumors from the two patients. If gene expres-
sions from FFPE RNA-seq reflect cancer biology then fold
changes should be similar whether the tumor was assessed
by RNA-seq or an established platform such as qPCR.
This was indeed the case (Figure 5A,B). Possibility of FFPE
RNA containing biologic information was further sup-
ported by hierarchical cluster analysis performed using
RCC genes (Figure 5C,D). The expression profiles clus-
tered based on tumor rather than method used to preserve
the tumor, i.e. FF vs FFPE.
It is well established that high quality RNA from FF tis-
sue can differentiate between high and low risk tumors.
Our tumors were clinically high risk tumors based on
stage and grade (Additional file 3: Table S3). They posed
high risk for metastatic recurrence even after surgical re-
moval of the primary tumor. To calculate fold change
using tumors considered low risk, patients with small, low
grade tumors were selected from TCGA. TCGA data wasfrom FF tumors. Expression fold changes were calculated
using high risk and low risk tumors. If RNA using FFPE
tumors can provide the same biologic information as FF
tumors, the fold changes determined using FF or FFPE
RCCs should correlate well. This is indeed the case with
an r of 0.887 (Figure 6).
Discussion
The past decade has seen accelerated development of
genomic and transcriptomic techniques. A wealth of
biologic insights has come from data generated from
thousands of tumor samples. Both the cost and turn-
around time have dropped dramatically, which in turn,
has put this powerful technology within reach of most
wet-lab scientists. RNA-seq has become the method of
choice for transcriptome profiling. In contrast to micro-
array and qPCR technologies, RNA-seq can identify
novel transcripts, examine all RNA species, and identify
alternative splices and mutations.
RCC has been studied using RNA-seq [7,22]. These
studies provide transcriptomic profiles for understanding
disease development and prognosis. However, all of these
Figure 2 Library size measurement by E-gel®. The average size
for all the libraries is approximately 300 bp. Lane 1: Tumor 1, FFPE;
Lane 2: Tumor 2, FFPE; Lane 3: Tumor 1, FF; Lane 4: Tumor 2, FF;
Lane M: 50 bp marker. FF, fresh frozen; FFPE, formalin-fixed
paraffin-embedded.
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tumors are relatively scarce. On the other hand, FFPE
samples are widely available because they are routinely
stored by all pathology departments. Importantly, FFPE
samples often come from patients who have had years ofFigure 3 Correlation of RNA-seq for FF and FFPE tumors. A) FFPE vs. F
genes C) FFPE vs. FF, tumor 1, RCC genes D) FFPE vs. FF, tumor 2, RCC gen
ΔCT. For RNA-seq, r was calculated using the log2 FPKM for genes with FP
FPKM, fragments per kilobase of exon per million fragments mapped.clinical follow-up. Therefore, this clinical annotation can
provide the phenotype needed to understand the genomic
and molecular data that can now be readily generated.
There are several studies of RNA-seq on FFPE tissue
[11-13]. However, all these studies have important limi-
tations. One of the studies used poly-A selection to cap-
ture mRNA and exclude ribosomal RNA. This results in
the loss of all non-mRNAs and because FFPE RNA is
highly degraded, poly-A capture provides only a limited
sequence from the 3’ end of the mRNA. Therefore, no
information is usually available on alternative splicing
and many mutations will be missed [12]. Another study
used lungs from two patients who died of influenza to
perform FFPE RNA-seq. However, the study profiled
viral RNA and not human RNA [13]. A third study from
Genomic Health Inc. used FFPE breast cancers; however,
there was no comparison with RNA-seq performed with
FF breast cancer [11]. This study did establish that the
expression of a prognostic signature based on a limited
number of genes can be determined using FFPE qPCR
or FFPE RNA-seq.
We performed whole-transcriptome RNA-seq on FFPE
and FF samples. We demonstrated that gene expressions
measured by RNA-seq using FFPE tissue correlate well
with FF RNA-seq. Our findings are consistent with a
recent report using a similar next-generation sequencing
platform as ours to compare RNA from paired FF and
FFPE tissue from a variety of tumor types to report a
correlation coefficient of 0.90 [14]. This study examinedF, tumor 1, all RNA-seq genes B) FFPE vs. FF, tumor 2, all RNA-seq
es E) For qPCR, r (Pearson’s correlation coefficient) was calculated using
KM > = 0.01. FF, fresh frozen; FFPE, formalin-fixed paraffin-embedded;
Figure 4 Correlation of RNA-seq and qPCR for FF and FFPE tumors. A) Tumor 1, FFPE B) Tumor 1, FF C) Tumor 2, FFPE D) Tumor 2, FF E)
r (Pearson’s correlation coefficient) and ρ (Spearman’s rank correlation) were calculated using the log2 FPKM and -ΔCT for the RCC genes. FF, fresh
frozen; FFPE, fresh-frozen paraffin-embedded; FPKM, fragments per kilobase of exon per million fragments mapped.
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tissues from bladder, prostate, liver, colon and tonsil. In
our study, we examined clear cell RCC. In addition to
RNA-seq, we also used qPCR as an established standard
for expression profiling and showed good correlation
with FFPE RNA-seq. By assessing fold change between
patient tumors and performing hierarchical cluster ana-
lysis, we showed that FFPE RNA-seq contains potentially
meaningful biologic information that can be used for
basic discoveries as well as patient care.
A limitation of our study is that we only examined two
patient tumors. However, RNA-seq outputs covering the
entire transcriptome provide ample data for a robust
analysis. Furthermore, use of multiple technology plat-
forms and use of the publically available TCGA results
strengthen our conclusion. FFPE tumors, routinely
stored by medical centers, are associated with a wealth
of clinical data and follow-up information. However, to
take advantage of these annotated tissues, RNA-seq
needs to be applied to large numbers of archival tissue.
Our study, along with other recent, independent reports,
establishes the feasibility of RNA-seq for these future
studies.
Conclusion
We demonstrated that gene expressions measured by
RNA-seq using FFPE tissue correlate well with two dif-
ferent gold standards: FF RNA-seq and qPCR.FFPE RNA-seq also provided biological information:
The expression profiles from the matched FF and FFPE
tissue clustered together. The fold change between high
risk FF tumor and TCGA low risk tumors correlated
well with the fold change between high risk FFPE tumor
and TCGA low risk tumors.
Our study suggests that FFPE RNA-seq can be used
for basic discoveries as well as clinical applications.
Methods
Patients and tissues
Cedars-Sinai Medical Center Biobank (Los Angeles, CA)
provided 4 renal tumors from 2 matching pairs of FFPE
and FF ccRCCs. The study was approved by Cedars-
Sinai Medical Center’s Institutional Review Board (IRB).
For prospectively collected tumor tissue, patients gave
written informed consent for data and tissue collection.
For FFPE tissue, which already existed in our biobank,
IRB provided an exemption for obtaining informed con-
sent. The clinical information associated with each
tumor is listed in Additional file 3: Table S1. The FFPE
tissues had been stored for about two years at room
temperature prior to use in this study.
RNA Extraction
Our method for RNA extraction has previously been de-
scribed [15,16,23]. Briefly, for FFPE tissue, RNA from six
10-μm sections were extracted using the MasterPure™
Figure 5 Potential for biological information. A) Correlation of expression fold change (between tumor 1 and tumor 2, FFPE) determined
using qPCR and RNA-seq. B) Same analysis using FF tumors. C) Hierarchical clustering based on RCC genes for all four samples after RNA-seq
D) Same analysis based on qPCR results. FF, fresh frozen; FFPE, fresh-frozen paraffin-embedded.
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WI) with minor modification: 200 ug Proteinase K was
added to the Cell Lysis Solution and used for a 3-hr incuba-
tion. For FF tissue, RNA was extracted from 100 mg ofsnap-frozen tissues using TRIzol®. RNA from both FFPE
and FF was treated with 20 units DNase I. Complete diges-
tion of genomic DNA was confirmed by TaqMan qPCR for
ACTB. The final RNA concentration and purity were
Figure 6 Correlation of fold changes using FFPE vs FF tumors.
The tumors from our institutional biobank were high risk tumors. To
calculate expression fold changes between high risk and low risk
tumors, low risk tumors (all FF tumors) were identified from The
Cancer Genome Atlas (TCGA). Genes highly expressed by RNA-seq
in both our institutional tumors and TCGA tumors were used to
calculate fold change. The correlation between fold changes
determined from FFPE and FF tumors is shown. The fold change
was calculated using log2 FPKM. HR, high risk tumors from our
institution; LR, low risk tumors from TCGA; FPKM, fragments per
kilobase of exon per million fragments mapped.
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eter (NanoDrop Technologies, Wilmington, DE). The in-
tegrity of RNA was measured with the Eukaryote Total
RNA Nano Assay of the Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA). 200 ng of RNA was loaded
for each sample.
RNA-seq Library preparation and sequencing
Ribosomal RNA was depleted from 4 micrograms of
total RNA using the Ribo-Zero™ Magnetic Kit (Epicentre
Biotechnologies, Madison, WI) following the manufac-
turer’s procedure. Sequencing libraries for whole tran-
scriptome analysis were prepared using ScriptSeq™ v2
RNA-Seq Library Preparation Kit (Epicentre Biotechnologies,
Madison, WI) following the manufacturer’s procedure.
After 3′-terminal tagging, the di-tagged cDNA was
purified using MinElute PCR Purification Kit (Qiagen,
Valencia, CA). Four 6-base index sequences were used
to prepare bar-coded libraries for sample multiplexing
(ScriptSeq™ Index PCR Primers (Set 1); Epicentre Biotech-
nologies, Madison, WI). PCR was carried out through 13
cycles to generate the second strand of cDNA, incorporate
barcodes, and amplify libraries. The amplified libraries
were size selected by a solid phase reversible immobilization,
paramagnetic bead-based process (Agencourt AMPure XP
system; Beckman Coulter Genomics, Danvers, MA). The
beads: PCR product ratio was 1.8:1.
Libraries were quantified by Qubit® dsDNA HS Assay
(Life Technologies, Carlsbad, CA). 15ng libraries were vi-
sualized on a 2% E-Gel (Life Technologies, Carlsbad, CA).
The four RNA-seq Libraries were then multiplexed in a
single lane on a paired end flow cell; clonal amplificationwas performed using an Illumina cBot (Illumina Inc.; San
Diego, CA). Sequencing-by-Synthesis chemistry was per-
formed on an Illumina Genome Analyzer IIX using 35 bp
single end sequencing chemistry.
BCL files were converted to FASTQ files using BCLcon-
verter. The FASTQ files were aligned against human gen-
ome reference version 19 (or hg19), using TopHat2 (http://
ccb.jhu.edu/software/tophat/index.shtml) software package.
Transcripts were assembled using Cufflink2 (http://cuf-
flinks.cbcb.umd.edu/). The number of sequenced reads
that align to a gene of interest was conventionally called a
tag count. To make tag count comparable among samples,
we transformed the tag count into FPKM/RPKM (Reads
per kilobase per million reads mapped) for normalization,
which is widely used in RNA-seq analysis. FPKM value was
shown in Additional file 3: Table S4.
To get RNA-seq quality metrics, bedtools utility (http://
bedtools.readthedocs.org) was used to overlap TopHat2
mappings with mapping quality of at least 20 and defined
exons and introns with a minimum overlap fraction of .8.
To reconcile differing exon and intron annotations for a
single gene due to alternative splicing, a read was defined
as intronic if it was (1) within an intron and (2) overlapped
with no exons; reads overlapping any exon were counted as
exonic. The bedtools utility was used to determine con-
cordance between the strands of reads mapping to exons
and the strands of the exons. To determine the presence of
rRNA in the samples, reads were mapped to rRNA human
sequences (NR_003287/RNA28S5, NR_003286/ RNA18S5,
NR_003285/RNA5-8S5, and NR_023379/ RNA5S17) using
the BWA utility (http://bio-bwa.sourceforge.net). Reads
which mapped to an rRNA sequence with a mapping qual-
ity of at least 20 were considered to be rRNA derived.
TaqMan qPCR using the open array platform
Reverse transcription (RT) was performed using the
High Capacity cDNA Reverse Transcription Kit (Life
Technologies, Grand Island, NY) following the manufac-
turer’s procedure. Each RT reaction contained 150ng of
total RNA, 1 μl of 10× RT buffer, 0.5 μl of 25× dNTP
mixture, 1 μl of 10× random reverse primers, 1 μl of
10× gene-specific reverse primers (1μM) and 0.5 μl of
MultiScribe RT (50 U/μl). The 10 μl reactions were in-
cubated in a Life Technologies Thermocycler for 10 min
at 25°C, 2 hours at 37°C and then held at 4°C. The
same primers were used for the pre-amplification and
the TaqMan qPCR. The 3’end primers used in the PCR
were used for the RT.
Preamplification was performed using the TaqMan® Pre-
Amp Master Mix Kit (Life Technologies, Grand Island,
NY). Each reaction included 2.5 μl of 2× TaqMan® PreAmp
Master Mix, 1.25 μl of 0.09× pooled TaqMan assays (Taq-
Man primers and probe) and 1.25 μl of cDNA. The reac-
tions were incubated in a Life Technologies Thermocycler
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seconds and 60°C for 4 min, and then held at 4°C. 0.09×
pooled Taqman assays were prepared by combining equal
volumes of each 20× Taqman assay (needed for PCR on the
Openarray®, 218 assays for each set). Each cDNA was pre-
amplified on two sets of 218 pooled assays.
The two sets of OpenArray plates were custom made.
The preamplified products were diluted 1:10; 10 μl of di-
luted cDNA was mixed with 10 μl of TaqMan Real-time
PCR OpenArray Master Mix (Life Technologies, Grand
Island, NY). The pre-amplified cDNA samples were dis-
pensed using the Accufill System onto the correspond-
ing OpenArray plate containing 218 gene assays. Twelve
cDNA samples were tested simultaneously per plate,
with 36 samples per qPCR run on the Openarray® NT
Cycler system. Post-acquisition data processing gener-
ated fluorescence amplification for each assay, from
which cycle threshold (CT) were computed. CT value
was shown in Additional file 3: Table S5.TCGA RNA-seq data mining and analysis
Clinical information and Level 3 RNA-seq FPKM data were
retrieved from the TCGA data portal (https://tcga-data.nci.
nih.gov/tcga/). Our tumors were clinically localized tumors
that posed high risk for metastasis. To compare these tumors
to low risk-RCC using expression fold change, all pT1N0M0,
grade 1 or 2 ccRCCs were selected from TCGA (n = 53).
To assess the distribution of FPKMs for all the genes,
box plots were generated (Additional file 2: Figure S2).
The goal was to identify the most highly expressed
genes. The FPKM distribution was different between
TCGA data and our data. One of the reasons is that we
used different platform for sequencing. TCGA used
Hiseq2000. We used GAIIx. Another reason is that we
sequenced different cohorts. Based on the distribution
of FPKMs, an average FPKM >10 was used to select
genes from the TCGA samples. For our samples, an
average FPKM >5 was used to select genes. A total of
3,195 overlapping genes common to both datasets were
identified and used to calculate expression fold changes
between our tumors and TCGA tumors.Statistics and bioinformatics
Fold changes in gene expression were calculated: for
qPCR results, log2 fold change between sample a and
b = Δ CT for b - Δ CT for a, and for RNA-seq results,
fold change between sample a and b = log2 (FPKM for a/
FPKM for b). Complete-linkage Hierarchical clustering
was performed using Gene Cluster 3.0 software. The
similarity (distance) between gene expression data was
defined using Pearson correlation (uncentered). The re-
sult was viewed using Java TreeView software.Availability of supporting data
The TCGA sequence data and clinical data discussed in this
publication are available from the TCGA Data Portal [7].
The supplemental data was available from LabArchive with
DOI of 10.6070/H4Q23X6N DOI: 10.6070/H4Q23X6N#doi.
Deep sequencing files have been deposited into Sequence
Read Archive under accession number SRP050335.
Additional files
Additional file 1: Figure S1. RNA integrity test before and after
Ribo-zero treatment. 200ng of RNA was measured with the Eukaryote
Total RNA Nano Assay of the Agilent 2100 Bioanalyzer. FF, fresh frozen;
FFPE: formalin-fixed paraffin-embedded; Before, before ribo-zero
treatment; After, after ribo-zero treatment.
Additional file 2: Figure S2. Box Graph for RNA-seq. Distribution of
FPKMs determined from RNA-seq. Horizontal line inside the box is the
median expression. The box contains expressions between the 25th and 75th
percentile. TCGA, The Cancer Genome Atlas RCC; CS FF, Cedars Sinai fresh
frozen RCC; CS FFPE, Cedars Sinai formalin-fixed paraffin-embedded RCC.
Additional file 3: Supplemental Tables.
Additional file 4: Figure S3. Distribution of detected genes for RNA-seq.
Transcript counts are plotted against Log2 (FPKM) for genes determined from
FF and FFPE RNA-seq. FF, fresh frozen; FFPE, fresh-frozen paraffin-embedded;
FPKM, fragments per kilobase of exon per million fragments mapped.
Additional file 5: Figure S4. Rank correlation of RNA-seq and qPCR for
matched FF and FFPE tumors. A) Tumor 1, FFPE B) Tumor 1, FF C) Tumor 2,
FFPE D) Tumor 2, FF. FF, fresh frozen; FFPE, fresh-frozen paraffin-embedded;
FPKM, fragments per kilobase of exon per million fragments mapped.
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